Prenatal blood typing study for HDFN
Part of Blood & lymphatic, Women’s health & pregnancy clinical trials.
This study tests a new DNA-based method to determine a baby's blood type before birth, which helps doctors manage pregnancies at risk for hemolytic disease of the fetus and newborn (HDFN). It aims to improve care for mothers with blood type incompatibility.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are pregnant and have developed antibodies against your baby's red blood cells (alloimmunization).
- You are receiving care in one of the participating regions during the study period.
- Your pregnancy has not ended in miscarriage or termination for reasons other than severe alloimmunization.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks pregnancies affected by hemolytic disease of the fetus and newborn (HDFN). It collects information to better understand the condition and improve care. You may join if you are pregnant with a history of a prior affected pregnancy and have a current antibody that could harm your baby.
This study tests a safer blood test to check for certain genetic disorders during pregnancy, instead of an invasive procedure like amniocentesis. It's for pregnant women who are at risk of passing on a known genetic condition.
This study tests a new blood test that can screen for genetic problems in babies during pregnancy. It may find more conditions than standard tests, especially for pregnancies with certain ultrasound findings or other risk factors.
This study tests a new blood test during early pregnancy that can screen for certain genetic conditions by analyzing fetal cells. A simple blood draw may help detect potential chromosomal abnormalities earlier and more safely than traditional methods.
This Phase 3 trial tests nipocalimab (an antibody medicine) to help prevent severe blood breakdown in a baby when a parent has certain blood antibodies. It enrolls people who previously had severe hemolytic disease in a past pregnancy and who are currently early in pregnancy with the same risk antibodies.
This study looks for the underlying cause of “non-immune hydrops fetalis,” a serious condition where a baby has abnormal fluid buildup. It focuses on families whose usual genetic tests didn’t find an answer (or weren’t completed before birth).
Hear when a new Next Generation Sequencing (NGS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.